Two small-cap pharmaceutical companies are being compared across multiple financial and operational metrics to assess their relative investment profiles.
Ownership and Institutional Investment
Citius Pharmaceuticals has significantly stronger institutional backing, with 16.9% of shares owned by institutional investors compared to 4.3% for NRx Pharmaceuticals. Insider ownership is similar between the two, with Citius at 5.0% and NRx at 6.4%.
Valuation and Financial Performance
NRx Pharmaceuticals demonstrates higher revenue and earnings than Citius Pharmaceuticals, according to the comparison. NRx also trades at a lower price-to-earnings ratio, positioning it as the more affordable option on a valuation basis. Overall, NRx Pharmaceuticals outperforms Citius on 9 of the 12 factors compared between the two stocks.
Risk Profiles
The companies differ substantially in volatility. Citius Pharmaceuticals has a beta of 1.05, indicating its share price is 5% more volatile than the S&P 500. NRx Pharmaceuticals presents considerably higher volatility with a beta of 2.02, meaning its share price is 102% more volatile than the S&P 500.
Company Profiles
Citius Pharmaceuticals, founded in 2007 and headquartered in Cranford, New Jersey, operates as a late-stage pharmaceutical company developing critical care products. Its pipeline includes LYMPHIR for cutaneous T-cell lymphoma in Phase 3 trials; Mino-Lok, an antibiotic lock solution in Phase 3; Halo-Lido for hemorrhoid relief in Phase 2b; Mino-Wrap for tissue expander infections; and NoveCite, a mesenchymal stem cell therapy for acute respiratory disease syndrome.
NRx Pharmaceuticals, founded in 2015 and based in Wilmington, Delaware, focuses on central nervous system disorder treatments. Its lead candidates include NRX-101, a fixed-dose combination receiving FDA breakthrough therapy designation for suicidal treatment-resistant bipolar depression, and NRX-100, a ketamine formulation with FDA fast track designation for severe bipolar depression with acute suicidal ideation. NRx maintains partnerships with Alvogen Inc., Lotus Pharmaceutical Company, Nephron Pharmaceuticals, Alcami, Apkarian Technologies, Glytech, and Sarah Herzog Memorial Hospital.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.thelincolnianonline.com/2026/05/24/citius-pharmaceuticals-nasdaqctxr-versus-nrx-pharmaceuticals-nasdaqnrxp-head-to-head-contrast.html